EVis Bioscience Recognized Among Europe’s Top Cell and Gene Therapy Companies
EVis Bioscience has been awarded the title “Top Targeted Gene Therapy Medicines Development Company in Europe 2026” by Life Sciences Review Europe, recognizing its leadership in precision RNA therapeutic development.
The award acknowledges companies demonstrating technological differentiation, translational relevance, and measurable innovation within the European gene therapy sector.
Why EVis Was Selected
The recognition highlights EVis Bioscience’s proprietary hybrid RNA delivery platform, which integrates:
- Stabilized extracellular vesicles
- Engineering-driven loading control
- Target-specific biological alignment
- Scalable, development-ready manufacturing
This architecture addresses fundamental limitations in gene therapy development, including delivery efficiency, safety constraints, and production bottlenecks.
Strategic Implication
Receiving this 2026 distinction reinforces EVis Bioscience’s positioning as a precision-focused RNA delivery innovator and strengthens its visibility within the European advanced therapeutics ecosystem.
The award reflects growing industry acknowledgment of the company’s platform potential as it advances toward expanded preclinical validation and broader strategic partnerships.
